Extrait

The primary objective of Study H3E-MC-JMHW (JMHW) was to estimate the response rates to pemetrexed administered intravenously every 21 days in children with relapsed or refractory osteosarcoma, Ewing sarcoma/peripheral PNET, rhabdomyosarcoma, neuroblastoma, ependymoma, medulloblastoma/supratentorial PNET, or non-brainstem high-grade glioma and to further define and describe the toxicities of pemetrexed.

Critère d'inclusion

• Recurrent Malignancies (recurrent solid tumors): Target tumor types were osteosarcoma, Ewing sarcoma/peripheral
• PNET, rhabdomyosarcoma, neuroblastoma (measurable disease), neuroblastoma (metaiodobenzylguanidine
• [MIBG]+ evaluable disease), ependymoma, medulloblastoma/supratentorial PNET, and non-brainstem
• high-grade glioma

Liens

• euctr